Metrifonate trial in the treatment of various presentations of Schistosoma haematobium and S. mansoni infections in the Sudan.
The effect of metrifonate (Bilarcil Bayer) on Schistosoma haematobium and S. mansoni infections was studied in 174 patients near Khartoum. A high cure rate was obtained in S. haematobium infections, but anthelmintic efficacy was minimal in patients passing S. mansoni eggs in their stools. There was, however, a marked reduction of egg output in patients passing S. mansoni eggs in urine. This suggests that the site of infection in man, rather than the species of parasite, renders the parasite more susceptible to metrifonate. The significance of this and the possibility that these results further clarify the mode of action of metrifonate are discussed.
D000293:Adolescent; D000328:Adult; D002648:Child; D002986:Clinical Trials as Topic; D005243:Feces / Q000469:parasitology; D005260:Female; D006801:Humans; D007411:Intestinal Diseases, Parasitic / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010270:Parasite Egg Count; D012548:Schistosoma haematobium; D012550:Schistosoma mansoni; D012552:Schistosomiasis / Q000188:drug therapy*; D013397:Sudan; D014236:Trichlorfon / Q000009:adverse effects / Q000627:therapeutic use*; D014556:Urine / Q000469:parasitology
D014236:Trichlorfon